title: Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006-2011).
abstract: Anticoagulant and antiplatelet medications are necessary in peripheral endovascular intervention, but a standardized approach has not yet been established. Glycoprotein IIb/IIIa inhibitor use in endovascular lower extremity interventions decreased overall amputation rates. Glycoprotein IIb/IIIa inhibitor use in endovascular lower extremity interventions increased postprocedural bleeding and complications requiring intervention.
authors.affiliation: Department of Vascular Surgery, Baylor College of Medicine, Houston, Texas.
authors.forename: Angela
authors.initials: A
authors.lastname: Echeverria
authors.affiliation: Department of Cardiology, Texas Heart Institute, Houston, Texas. abadheka@everettclinic.com.
authors.forename: Zvonimir
authors.initials: Z
authors.lastname: Krajcer
mesh_terms: D006801:Humans; D007297:Inpatients; D035002:Lower Extremity / Q000098:blood supply; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex